BioCentury
ARTICLE | Strategy

Let a thousand ideas bloom

How Shire is breaking the mold to fuel external discovery in rare diseases

May 20, 2013 7:00 AM UTC

Shire plc has long been a growth through acquisition company, but the pace of its external discovery is picking up steam and the company now has over 20 ongoing projects to show for it.

Traditional research collaborations are target- or MOA-driven, with the pharma or biotech supporting academic institutions that have a program focused on a particular disease-related gene or a novel disease pathway...